Estrogen-progestagen therapy in the management of the polycystic ovary syndrome (Q30472945)

21 June 2017

1 reference

title

Estrogen-progestagen therapy in the management of the polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

21 June 2017

1 reference

1 reference

Marshall JC

1

1 reference

21 June 2017

1 October 1998

1 reference

Journal of Endocrinological Investigation

21 June 2017

1 reference

21 June 2017

21

1 reference

21 June 2017

9

1 reference

21 June 2017

618-622

1 reference

Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

21 June 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

The effects of the aromatase inhibitor delta 1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Serum steroids and pituitary hormones in female puberty: a partly longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03350787

Increased luteinizing hormone and alpha-subunit secretion in women with hyperandrogenic anovulation

21 January 2018

1 reference

12 December 2020

Relevance of biological properties of progestogen of oral contraceptives in treatment of androgen excess symptoms

1 reference

12 December 2020

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

1 reference

12 December 2020

The frequency of gonadotropin-releasing-hormone stimulation differentially regulates gonadotropin subunit messenger ribonucleic acid expression

1 reference

12 December 2020

Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone

1 reference

12 December 2020

Continuous gonadotropin-releasing hormone for ovulation induction in polycystic ovarian disease.

1 reference

12 December 2020

Endocrine Determinants of Fertility: Serum Androgen Concentrations during Follow-up of Adolescents into the Third Decade of Life*

1 reference

12 December 2020

Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation.

1 reference

12 December 2020

Clinical review 73: Medical treatment of androgen-dependent hirsutism.

1 reference

12 December 2020

Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome

1 reference

12 December 2020

Progesterone modulation of pulsatile luteinizing hormone secretion in normal women

1 reference

12 December 2020

Induction of ovulation by cyclical hormone therapy

1 reference

12 December 2020

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

12 December 2020

Can metformin reduce insulin resistance in polycystic ovary syndrome?

1 reference

12 December 2020

Hormonal effects of flutamide in young women with polycystic ovary syndrome

1 reference

12 December 2020

Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women

1 reference

12 December 2020

Comparison of the efficacy of spironolactone**Spironolactone (Aldactone; Searle, Chicago, IL). versus flutamide††Flutamide (Eulexin; Schering Plough Laboratories, Heist, Belgium). in the treatment of hirsutism‡‡Presented in part at the 3rd Wo

1 reference

12 December 2020

Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial**Supported in part by Schering-Plough, Pointe-Claire, Québec, Canada

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03350787

1 reference

PubMed ID

9856416

Dimensions Publication ID

21 June 2017

0 references

1 reference

PubMed ID

9856416